ELMO2-IN-1
ELMO2-IN-1 is an ELMO2 inhibitor with a human target Kd of 1.0 µM. ELMO2-IN-1 binds to ELMO2, disrupting its function. ELMO2-IN-1 induces autophagy-dependent cell death. ELMO2-IN-1 can be used for the research of non-small cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 1216514-48-5
- Formula: C29H28N4O2
- Molecular Weight:464.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
ELMO2-IN-1 (Compound C52) (200 μM) binds specifically to wild-type ELMO2 with a Kd of 1.05 μM, and the HIS-435 residue is essential for this binding[1].
ELMO2-IN-1 (72 h) selectively suppresses viability of mesenchymal-like NSCLC cell lines including NCI-H1299, A549, NCI-H1703, 95D, and NCI-H1792 in a concentration-dependent manner, has no effect on normal lung cell lines HBE and MRC-5, and its activity depends on ELMO2 binding and ELMO3 expression levels[1].
ELMO2-IN-1 (5-10 μM; 6-24 h) suppresses FAKY397 phosphorylation in a concentration and time-dependent manner, and induces autophagy markers (reduced p62, increased LC3-II/LC3-I ratio) in mesenchymal-like NSCLC cell lines NCI-H1299 and A549[1].
ELMO2-IN-1 induces cell death in mesenchymal-like patient-derived NSCLC organoids with low ELMO3 expression, but not in epithelial-like organoids with high ELMO3 expression[1].
ELMO2-IN-1 (72 h) potently reduces viability of Osimertinib-resistant NSCLC cell lines NCI-H1975-OR (IC50 = 5.88 μM) and HCC827-OR (IC50 = 7.63 μM), and induces autophagy-related changes in these resistant cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:mesenchymal-like NSCLC cell lines (NCI-H1299, A549)
-
Concentration:5 μM; 10 μM
-
Incubation Time:6 h; 12 h; 24 h
-
Result:Suppressed FAK phosphorylation at the Y397 site in a concentration-dependent and time-dependent manner.
Reduced p62 protein expression.
Increased the LC3-II/LC3-I ratio, consistent with induction of autophagy.
In Vivo
ELMO2-IN-1 (25 mg/kg; i.p.; daily for 30 days) does not inhibit the growth of epithelial-like PC-9 non-small cell lung cancer xenografts in female BALB/c nude mice[1].
ELMO2-IN-1 (25 mg/kg; i.p.; daily for 30 days) completely inhibits the growth of Osimertinib (HY-15772)-resistant NCI-H1975-OR non-small cell lung cancer xenografts in female BALB/c nude mice, with no activity against parental NCI-H1975 tumors[1].
ELMO2-IN-1 (25 mg/kg; i.p.; daily for 30 days) does not inhibit the growth of A549 non-small cell lung cancer xenografts expressing ELMO2H435A mutant[1].
ELMO2-IN-1 (2.5-25 mg/kg; i.p.; daily) induces a dose-dependent antitumor response in mesenchymal-like A549 non-small cell lung cancer xenografts in female BALB/c nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, subcutaneous xenograft of mesenchymal-like A549 cells)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; daily for 30 days
-
Result:Achieved near-complete suppression of tumor growth.
By day 40, mean tumor volume remained near baseline, while vehicle-treated mice had a mean tumor volume of ~1600 mm3 (P<0.0001).
-
Animal Model:BALB/c nude (female, 6-8 weeks old, subcutaneous xenograft of epithelial-like PC-9 cells)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; daily for 30 days
-
Result:Showed no significant effect on tumor growth.
By day 40, mean tumor volume in treated and vehicle-treated mice was nearly identical (P=0.9973).
-
Animal Model:BALB/c nude (female, 6-8 weeks old, subcutaneous xenograft of osimertinib-resistant NCI-H1975-OR cells)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; daily for 30 days
-
Result:Completely suppressed tumor growth.
By day 40, mean tumor volume remained near baseline, while vehicle-treated mice had a mean tumor volume of ~1200 mm3 (P<0.0001).
Showed no effect on tumor growth in parental NCI-H1975 xenografts (P>0.9999).
-
Animal Model:BALB/c nude (female, 6-8 weeks old, subcutaneous xenograft of A549 cells expressing ELMO2-H435A mutant)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; daily for 30 days
-
Result:Failed to suppress growth of tumors expressing the ELMO2-H435A mutant, confirming on-target activity via binding to ELMO2's HIS-435 residue.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, subcutaneous xenograft of A549 cells)[1]
-
Dosage:2.5 mg/kg; 10 mg/kg; 25 mg/kg
-
Administration:i.p.; daily
-
Result:Exhibited a dose-dependent antitumor response in A549 xenografts.
Chemical Information
-
CAS No. 1216514-48-5
-
Molecular Weight 464.56
-
Formula C29H28N4O2
-
SMILES
CC(NC(CN1C2=C(C3=C1C(N(C=N3)CC4=CC=CC=C4)=O)C=CC=C2)=O)CCC5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)